CompletedPhase 3NCT00422084
Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients
Studying Malaria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Medicines for Malaria Venture
- Principal Investigator
- Claude Oeuvray, PhDMedicines for Malaria Venture
- Intervention
- Pyronaridine artesunate(drug)
- Enrollment
- 1272 target
- Eligibility
- 3-60 years · All sexes
- Timeline
- 2007 – 2008
Study locations (10)
- Ecole de Santé Publique, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
- Komfo Anoykye Teaching Hospital, Kumasi, Ghana
- RSUD TC Hillers, Maumere, Nusa Tenggara Timur, Indonesia
- Jayapura General Hospital (RSUD) DOK II, Jayapura, Special Region of Papua, Indonesia
- Siaya District Hospital, Medical Superintendent's office, Siaya, Kenya
- Malaria Research and Training Center, Faculté de Médecine, de Pharmacie et d'Ondonto-stomatologie, Bamako, Mali
- Instituto Nacional de Saude, Ministero de Saude, Maputo, Mozambique
- Puerto Princesa General Hospital, Puerto Princesa City, Philippines
- Service de Parasitologie, Faculté de Médecine, Université Cheikh Anta Diop, Dakar, Dakar Fann, Senegal
- Farafenni Field Station, c/o: MRC Laboratories, Fajara, The Gambia
Collaborators
Shin Poong Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00422084 on ClinicalTrials.govOther trials for Malaria
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07257965Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai AdultsUniversity of Oxford
- RECRUITINGPHASE2NCT07147400Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsSerum Institute of India Pvt. Ltd.
- RECRUITINGPHASE2NCT07036159A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 MonthsGlaxoSmithKline
- ACTIVE NOT RECRUITINGPHASE1NCT06735209First-in-Human PfSPZ-LARC2 Vaccination/CHMINational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT07060508L9LS in Women of Childbearing Potential in MaliNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06549257Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M AdjuvantUniversity of Oxford
- ACTIVE NOT RECRUITINGNANCT06599593Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and MalnutritionUniversity of California, San Francisco
- RECRUITINGPHASE4NCT07038837Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in ChadEpicentre